1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AHA 2023 – Wegovy Cuts Death Risk, But Will That Be Enough For Payers?

 
• By Elizabeth Cairns

The SELECT cardiovascular outcomes trial is a convincing hit; now Novo Nordisk must grapple with reimbursement and manufacturing.    

Novo Nordisk

Eli Lilly and Company may have just made its big move into obesity with this week’s approval of Zepbound (tirzepatide), but Novo Nordisk A/S is fighting back hard, and looks likely to take its obesity blockbuster Wegovy (semaglutide 2.4mg) to the next level.

Key Takeaways

  • Full SELECT data indicate a marked cut in the risk of death with Wegovy over placebo, setting it up for an indication expansion

  • It is not clear whether governments will pay for the drug for use in patients at risk of cardiovascular disease

Wegovy has a good chance of adding a cardioprotective claim to its label after cutting the risk of mortality in the SELECT trial, presented today at the annual meeting of the American Heart Association in Philadelphia, to a markedly greater degree than in a similar trial

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

More from R&D

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Which Firms Are Most Exposed To Prasad’s Possible Accelerated Approvals Clampdown?

 
• By Andrew McConaghie

Vaccine and accelerated approvals are expected to face greater scrutiny under new CBER leader Vinay Prasad, but he has promised “no light switch change” to policy, giving some reassurance to companies whose share prices have been battered.